Omniscan (Gadodiamide)

Gadodiamide, the active ingredient in Omniscan, is a contrast media presented as a gadolinium‑based agent for intravenous use in magnetic resonance imaging procedures. It enhances image quality to help visualize vascular structures and organ tissues. GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide.

GNH USA supplies Omniscan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, imaging centres and clinics worldwide.

Omniscan is used as a magnetic resonance imaging (MRI) contrast agent to improve the visibility of certain anatomical structures. - Central nervous system imaging: Enhances detection of lesions and tumors in the brain and spine. - Vascular imaging: Improves visual assessment of blood vessels and aneurysms. - Cardiac imaging: Assists in evaluating myocardial perfusion and function. - Abdominal and pelvic imaging : Provides greater detail for liver and renal structures in the abdomen and pelvis.

Adverse reactions to gadodiamide‑based contrast agents are generally uncommon but can occur.

Common Side Effects: - Nausea: Mild, transient feeling of stomach upset. - Headache: Temporary discomfort often resolving without treatment. - Injection site discomfort: Minor pain or burning at the infusion site. - Warmth sensation: Brief feeling of warmth or flushing.

Serious or Rare Side Effects: - Nephrogenic systemic fibrosis (NSF): A rare fibrotic disorder linked to gadolinium exposure in patients with severe renal impairment. - Anaphylactoid reaction: Acute allergic‑type response that may include hives, swelling or respiratory difficulty. - Severe hypersensitivity: Potential for bronchospasm or hypotension requiring emergency care. - Cardiac arrest: Extremely rare but life‑threatening event following administration.

When using Omniscan, clinicians should assess patient risk factors and follow recommended safety measures.

- Renal function assessment: Evaluate glomerular filtration rate before administration in patients with known kidney disease. - Pregnancy caution: Use only if the diagnostic benefit outweighs potential fetal risk. - Breastfeeding guidance: Consider discontinuing breastfeeding for a short period after injection. - Allergy history: Review prior reactions to gadolinium‑based agents or other contrast media. - Hydration encouragement: Ensure adequate fluid intake post‑procedure to aid renal clearance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Gadodiamide may interact with other substances that affect renal function or immune response.

Major Interactions (Avoid): - Nephrotoxic drugs: Concurrent use with high‑dose aminoglycosides or NSAIDs can increase risk of renal injury. - Iron‑based contrast agents: May interfere with gadolinium clearance and imaging quality.\nModerate Interactions (Monitor Closely): - Diuretics: May alter fluid balance, affecting gadolinium excretion. - Immunosuppressants: Potentially modify hypersensitivity risk. - Beta‑blockers: May mask early signs of anaphylactoid reactions. - Calcium channel blockers: No direct effect but monitor overall cardiovascular status.